Cemiplimab-Based Treatment in Advanced NSCLC With Liver Metastases: Updated Analysis From EMPOWER-Lung 1 and EMPOWER-Lung 3

被引：0

作者：

Baramidze, A. ^{[1
]}

Gessner, C. ^{[2
]}

Gogishvili, M. ^{[3
]}

Sezer, A. ^{[4
]}

Makharadze, T. ^{[5
]}

Kilickap, S. ^{[6
]}

Gumus, M. ^{[7
]}

Li, Y. ^{[8
]}

Li, S. ^{[8
]}

Salvati, M. ^{[8
]}

Pouliot, J. -F. ^{[8
]}

Seebach, F. ^{[8
]}

Lowy, I. ^{[8
]}

Gullo, G. ^{[8
]}

Rietschel, P. ^{[8
]}

机构：

[1] Todua Clin, Tbilisi, Georgia

[2] Univ Leipzig, Inst Clin Immunol, Leipzig, Germany

[3] Univ Clin Ltd, High Technol Med Ctr, Tbilisi, Georgia

[4] Baskent Univ, Adana, Turkiye

[5] LTD High Technol Hosp Med Ctr, Batumi, Georgia

[6] Istinye Univ, Fac Med, Istanbul, Turkiye

[7] Istanbul Medeniyet Univ, Istanbul, Turkiye

[8] Regeneron Pharmaceut Inc, Tarrytown, NY USA

来源：

关键词：

Cemiplimab; Liver metastases; Advanced NSCLC;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.06-01

引用

页码：S316 / S317

页数：2